An expert retina specialist discusses the recent FDA-approved treatments for geographic atrophy (GA) that slow disease progression and highlights key factors to consider before starting treatment.
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Spotlighting telemedicine in the year of a pandemic
New treatment options provide effective management of geographic atrophy
Merger of Akari Therapeutics, Plc and Peak Bio, Inc. is complete
Identifying and monitoring GA: Technologic improvements over time
New data on PST-611 from PulseSight Therapeutics SAS shared at EVER Congress 2024